SA519401787B1 - تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها - Google Patents

تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها

Info

Publication number
SA519401787B1
SA519401787B1 SA519401787A SA519401787A SA519401787B1 SA 519401787 B1 SA519401787 B1 SA 519401787B1 SA 519401787 A SA519401787 A SA 519401787A SA 519401787 A SA519401787 A SA 519401787A SA 519401787 B1 SA519401787 B1 SA 519401787B1
Authority
SA
Saudi Arabia
Prior art keywords
preventing
pharmaceutical composition
preparing same
brain cancer
treating brain
Prior art date
Application number
SA519401787A
Other languages
English (en)
Inventor
الثالث جو باى
زينجلين لين
Original Assignee
شيماس كو . ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by شيماس كو . ليمتد filed Critical شيماس كو . ليمتد
Publication of SA519401787B1 publication Critical patent/SA519401787B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G28/00—Compounds of arsenic
    • C01G28/005—Oxides; Hydroxides; Oxyacids
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/60—Compounds characterised by their crystallite size
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/80—Compositional purity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية pharmaceutical composition للوقاية من سرطان المخ brain cancer أو علاجه وتشتمل على 99٪ على الأقل من متعدد أشكال بلورية أ لمركب سداسي أكسيد الزرنيخ الرباعي tetraarsenic hexoxide crystalline polymorph a (As406-a)، وبطريقة لتحضير هذه التركيبة. تظهر تركيبة وفقًا للاختراع الحالي تثبيط انتشار خلايا سرطانية cancer cell بدرجة فائقة وتحقق نتائج مثبطة للانتشار السرطاني الثانوي metastasis inhibition effects، وبالتالي تكون مفيدة كعامل مضاد للسرطان anti-cancer agent. شكل1
SA519401787A 2016-11-18 2019-05-14 تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها SA519401787B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160154409A KR101755556B1 (ko) 2016-11-18 2016-11-18 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
PCT/KR2017/009820 WO2018093029A1 (ko) 2016-11-18 2017-09-07 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법

Publications (1)

Publication Number Publication Date
SA519401787B1 true SA519401787B1 (ar) 2021-12-13

Family

ID=59353596

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519401787A SA519401787B1 (ar) 2016-11-18 2019-05-14 تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها

Country Status (16)

Country Link
US (1) US10493100B2 (ar)
EP (1) EP3542804B1 (ar)
JP (1) JP6824431B2 (ar)
KR (1) KR101755556B1 (ar)
CN (1) CN108066358B (ar)
AU (1) AU2017360407B2 (ar)
BR (1) BR112019009810A2 (ar)
CA (1) CA3043145C (ar)
CL (1) CL2019001344A1 (ar)
IL (1) IL266660B (ar)
MX (1) MX2019005737A (ar)
MY (1) MY196811A (ar)
PH (1) PH12019501110A1 (ar)
SA (1) SA519401787B1 (ar)
WO (1) WO2018093029A1 (ar)
ZA (1) ZA201902611B (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
HUE036571T2 (hu) 2013-04-19 2018-07-30 Incyte Holdings Corp Biciklusos heterociklusok mint FGFR inhibitorok
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3259269B9 (en) 2015-02-20 2020-03-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN108066359A (zh) * 2016-11-09 2018-05-25 凯马斯株式会社 包含六氧化四砷的用于抑制癌转移的药物组合物
KR101755556B1 (ko) * 2016-11-18 2017-07-07 주식회사 케마스 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko) * 2016-11-21 2018-03-05 주식회사 케마스 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko) * 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100272835B1 (ko) * 1998-05-08 2000-11-15 배일주 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물
US7261906B2 (en) * 1998-05-08 2007-08-28 Ill-Ju Bae Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition
KR100399657B1 (ko) * 2000-06-29 2003-09-29 배일주 혈관신생 억제제
KR20020095835A (ko) * 2001-06-16 2002-12-28 배일주 아폽토시스 유도제
CN1471925A (zh) * 2002-08-02 2004-02-04 丛繁滋 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
WO2009112266A1 (en) * 2008-03-12 2009-09-17 Ludwig-Maximilians-Universität Active substance combination with gemcitabine for the treatment of epithelial cancer
KR101572529B1 (ko) 2008-11-14 2015-11-27 배일주 암 치료를 위한 육산화사비소의 병용요법
KR101100786B1 (ko) * 2008-12-16 2011-12-29 (주)천지산 암에 대한 방사선 치료 증진용 조성물
KR101119587B1 (ko) 2011-03-10 2012-04-17 배일주 육산화사비소를 함유하는 용출률 및 안정성이 개선된 경구투여형 약제학적 제제
KR101755556B1 (ko) 2016-11-18 2017-07-07 주식회사 케마스 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
CA3043145A1 (en) 2018-05-24
EP3542804A1 (en) 2019-09-25
EP3542804A4 (en) 2020-05-27
ZA201902611B (en) 2020-11-25
US20190328779A1 (en) 2019-10-31
KR101755556B1 (ko) 2017-07-07
IL266660A (en) 2019-07-31
AU2017360407B2 (en) 2020-11-26
WO2018093029A1 (ko) 2018-05-24
BR112019009810A2 (pt) 2019-08-13
PH12019501110A1 (en) 2020-03-02
MX2019005737A (es) 2019-07-04
CN108066358B (zh) 2021-06-25
CA3043145C (en) 2021-11-09
JP6824431B2 (ja) 2021-02-03
IL266660B (en) 2021-09-30
EP3542804B1 (en) 2021-11-03
JP2020500219A (ja) 2020-01-09
MY196811A (en) 2023-05-03
US10493100B2 (en) 2019-12-03
AU2017360407A1 (en) 2019-06-20
CL2019001344A1 (es) 2020-02-21
CN108066358A (zh) 2018-05-25

Similar Documents

Publication Publication Date Title
SA519401787B1 (ar) تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها
SA519401785B1 (ar) تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجها
PH12019501292A1 (en) Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph
PH12019501220A1 (en) Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph
MX2018012016A (es) Compuestos biciclicos.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005780A (es) Moduladores de receptores estrogenicos.
MX2022000789A (es) Compuestos heterociclicos como inmunomoduladores.
PH12017502363A1 (en) Brk inhibitory compound
PH12017501925A1 (en) Pyrazole compounds and method for making and using the compounds
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
PH12019500196A1 (en) Compounds and compositions and uses thereof
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2019013419A (es) Compuestos plaguicidas biciclicos.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
PH12019500198A1 (en) Compounds and compositions and uses thereof
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives